Epstein-Barr virus regulates activation and processing of the third component of complement by unknown
EPSTEIN-BARR VIRUS REGULATES ACTIVATION
AND PROCESSING OF THE THIRD
COMPONENT OF COMPLEMENT
BY CAROLYN MOLD, BONNIE M. BRADT, GLEN R. NEMEROW,
AND NEIL R. COOPER
From the Department of Immunology, Research Institute of Scripps Clinic,
La Jolla, California 92037
Epstein-Barr virus(EBV), ahuman herpesvirus, is responsible for, or closely as-
sociated with a number of human diseases, including infectious mononucleosis,
nasopharyngeal carcinoma, Burkitt's lymphoma, an X-linked lymphoproliferative
syndrome, and several autoimmune diseases (1-6). EBV isoncogenic in subhuman
primates (7); in vitro it transforms normal human B lymphocytes, thereby gener-
ating immortal polyclonal B lymphoblastoid cell lines (8). EBV exhibits a highly
restricted celltropism; in vitro it only infectsBlymphocytes(9-11) and nasoepithelial
cells(12, 13) and only these cell types from patients contain the viral genome. Infec-
tion is initiated by binding ofEBV to CR2, the 145-kD B lymphocyte receptor for
the C3dg fragment of C3, the third complement component (14-17).
EBV exhibits several close associations with the complement system. First, EBV
uses CR2, a complement receptor to attach to and infect B lymphocytes (14-17);
second, the gp350 envelope glycoprotein ofEBV shares amino acid sequence ho-
mology with C3dg (18); third, lymphoblastoid cells carrying the EBV genome in
alatent state activate the alternative complement pathway(19); and, fourth, gp350,
intact EBV, and EBVproducingcellsalso activate the alternativecomplement pathway
(20, 21).
During complementactivationbyeither pathway, C3 and C4 arecleaved intotwo
fragments, C3a and C3b, and C4a and C4b, respectively. A proportion ofthe C3b
and C4b generated in such reactions becomes covalentlybound to the activator. In
the case ofseveral viruses, including EBV (22), this protein coating may neutralize
infectivity (reviewed in reference 23). In addition, C3b- and C4b-coated particles
bindto CR1 complement receptorsthatare foundonphagocytes, monocytes, erythro-
cytes, B lymphocytes, and other cells (reviewed in reference 24). Such attachment
to CRl on cells via a C3b or C4b bridge has various functional consequences. In
the case of EBV with attached C3b or C4b, the virus is redirected to CR1 rather
than the virus receptor (23), and isphagocytosed ifredirected toCRl on phagocytic
cells (23).
Activator bound C3b may be cleaved by aplasma enzyme, factor I, to yield iC3b
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which interacts with another complement receptor, CR3, found on phagocytic cells
(24, 25) (Fig. 1) . Further cleavage of iC3b by factor I yields C3c (140 kD) which
is released into the fluid phase, and C3dg (41kD) which remains covalently attached
to the activator (26-28). Additional proteolytic cleavage of C3dg to Cad (35 kD)
can be mediated by certain proteases (28) . Activator-bound C3dg or Cad interact
with other receptors termed CR2, found on B lymphocytes (15, 29) and CR4, present
on phagocytic cells and platelets (30, 31). Activator-bound C4 is cleaved by factor
I successively into iC4b and C4c and C4d (32, 33). These fragments have not been
reported to interact with CR3, CR2, or CR4.
Factor I requires the participation of cofactor proteins to cleave C3b, iC3b, C4b,
and iC4b. The serum proteins factor H (34) and C4 binding protein (C4bp)' (35),
and the cell membrane proteins CR1 (26, 27, 36), CR2 (37), and membrane cofactor
protein (MCP) (38) all act as cofactors for one or more I-mediated cleavage reac-
tions. Many of the proteins with cofactor activity also regulate the activation and
processing of C3 by accelerating decay-dissociation of the C3 activating enzymes
of the alternative and classical pathways (39-42). An additional cell membrane pro-
tein, decay-accelerating factor (DAF), lacks cofactor activity but regulates C3 ac-
tivating enzymes of both pathways (43, 44).
Certain of these regulatory activities are possessed by glycoprotein C of two her-
pesviruses, HSV1 (45-47) and HSV2 (48). In the course of examining the mecha-
nism of complement activation by EBV, we obtained evidence that EBV acted as
a cofactor for factor I-mediated cleavage of C3b. The results of these and further
studies indicate that EBV possesses factor I cofactor activity for not only the cleavage
of C3b, but also iC3b, C4b, and iC4b. EBV also accelerates the decay of the alterna-
tive pathway C3 convertase.
Materials and Methods
Viruses.
￿
EBV was purified from supernatants of 12-0-tetradecanoylphorbol-13-acetate
(TPA)-treated B95-8 and P3HR1 cells by gradient ultracentrifugation as previously described
(49). The final virus preparations had a concentration of N5 x 10" particles/ml as deter-
mined by quantitation ofDNA. Human cytomegalovirus (HCMV) was purified as described
(50), and the amount of infectious virus was determined by a standard plaque assay (51).
Complement Components and RelatedReagents.
￿
Marmoset erythrocytes were obtained through
the courtesy ofDr. Suzette Tardiff, Marmoset Research Center, Oakridge Associated University,
Oakridge, TN.
C3 was purifed by the method of Hammer et al. (52) with immunoadsorption used to re-
move albumin, C5, IgG, and IgA. C3 and C4 were radioiodinated with 12'1-sodium iodide
and lodobeads (Pierce Chemical Co., Rockford, IL) according to the manufacturer's instruc-
tions to a sp act of 2-4 x 105 cpm/gg. Factors B, D, H, I, and C4bp were kindly provided
in purified form by Drs. Leslie Leonard and Hans Miiller-Eberhard, Research Institute of
Scripps Clinic and Bernhard Nocht Institute, Hamburg, Federal Republic ofGermany, respec-
tively. Properdin was purified from the euglobulin of normal human serum by chromatog-
raphyon QAE-Sephadex A25 (Pharmacia Fine Chemicals, Uppsala, Sweden) in 0.15 M Tris
buffer (pH 9 .1, 4 mS). The breakthrough fractions were pooled, concentrated, and passed
over protein A-Sepharose (Pharmacia Fine Chemicals) followed by specific immunoadsor-
bent columns to remove Clq and IgG. Human C4 was purified as described (52). Human
C2 was purchased from Diamedix Corporation, Miami, FL.
' Abbreviations used in this paper: C4bp, C4 binding protein; DAF, decay-accelerating factor; GVB, 1%
gelatin, veronal-buffered saline; HCMV, human cytomegalovirus; MCP, membrane cofactor protein.MOLD ET AL.
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For assays of C3 cofactor activity, EAC142, prepared with human components and oxi-
dized human C2, were incubated for 20 min at 37°C with 1251-C3 (100 ug/5 x 108 cells),
washed and suspended in GVB (0.1% gelatin, veronal-buffered physiological saline, pH 7.4)
at 109 cells/ml. These EAC1423b were converted to EAC142iC3b cells by incubating for 30
min at 37°C with 80 gg offactor I and 70 gg of factor H/109 cells. The cells were then washed
and resuspended in GVB. For assays of C4 cofactor activity, sensitized sheep E were sequen-
tially incubated with human Cl and 1251-C4 (150 ug/109 cells), washed, and suspended in
GVB at 109 cells/ml. For rosetting assays, EAC142, EAC1423b, and EAC142iC3b were pre-
pared as above with the substitution of unlabeled human purified C3 for the 1251-C3 . Also,
portions ofthe EAC142iC3b cells were converted to EAC1423d by incubation at 109 cells/ml
for 30 min at 37°C with trypsinTPCK (Worthington Biochemical Corp., Freehold, NJ) (20
wg/ml) in GVB. After the incubation, the trypsin was neutralized by the addition of excess
soybean trypsin inhibitor and the cells were washed extensively.
For assays of decay-accelerating activity, EAC142 were prepared with limiting amounts
of nonoxidized C2 calculated to yield -0.5-1 hemolytic sites per cell. EAC3bBb were pre-
pared as follows: Native C3 was incubated with sheep erythrocytes (100 ug C3 for 109 E) and
5 gg trypsinTPCK in a total volume of 100 gl. The buffer used throughout this preparation
was GVB. The cells were incubated at 23 °C for 5 min and then washed thoroughly. EC3b
were incubated in a final volume of 100 pi with 20 gg of factor B, 0.5 gg of factor D, and
either 2 mM NiC12 or 7.5 gg of native properdin together with 2 mM MgC12 to stabilize
the convertase.
Antibodies.
￿
mAbs to a common class I HLA determinant, W6-32 (American Type Cul-
ture Collection, Rockville, MD), HLA-DQ and HLA-DR (Becton Dickinson & Co., Sun-
nyvale, CA), and BI (Coulter Immunology, Hialeah, FL) were obtained commercially. Mono-
clonal (3D9) and polyclonal anti-CR1 were kind gifts of Drs. Eric Brown (Washington
University, St. Louis, MO) and Brian Tack (Research Institute of Scripps Clinic) respec-
tively. Other mAbs to CR1 were purchased from Becton Dickinson & Co. (44D) and Ac-
curate Chemical Co., Hicksville, NY (833M), respectively. mAbs specific for C3b, C3c, and
Cad were kindly provided by Dr. Hans Miiller-Eberhard, Bernhard Nocht Institute, Ham-
burg, Federal Republic of Germany.
SDS-PAGE andAutoradiography.
￿
SDS-PAGE analyses were performed under reducing con-
ditions using the Laemitli buffer system on 10% gels or on 5-15% gradient gels (53). Samples
were boiled for 3 min before electrophoresis. Kodak X-Omat RP film was used for autoradi-
ography.
FACSAnalysis.
￿
Pellets of 106 Raji, B95-8, P3HR1, and TI human lymphoblastoid cells
as well as TPA-induced B95-8 cells were washed and resuspended on ice in 50-ul volumes
of the mAbs to be analyzed. Quantities of the monoclonals used were as follows: Anti-HLA-
DQ and DR and BI were used undiluted; mAb 3D9 (anti-CR1, prepared from ascites with
octanoic acid) was used at 5-20 ug/ml as specified; mAb W6-32 (anti-MHC class I clone)
was used at a 1 :4 dilution; mAb 44D (anti-CR1, Becton Dickinson & Co.) was used undiluted;
mAb 833M (Accurate Chemical Co.) was used at a 1 :10 dilution. All of the monoclonals
were centrifuged for 10 min at 10,000 g before use. The mAbs were incubated with the cells
for 1 h on ice and subsequently washed with ice cold PBS-BSA. The pellets were then
resuspended in 50 wl of 1 :10 diluted FITC-labeled affinity-purified goat anti-mouse IgG (y
chain specific; Kirkegaard & Perry Laboratories, Gaithersburg, MD) and incubated for 30
additional minutes on ice. The cells were washed and resuspended in 0.5 ml of PBS-BSA.
Fluorescence analyses were performed with a FAGS (model 440; Becton Dickinson & Co.)
equipped with a 5 W argon laseroperating at 488 nm, 0.3 W. Fluorescence parameters were
collected after gating for a combination of forward light scatter and orthogonal light scatter
(side scatter), used to discriminate viable from nonviable cells. Data were stored in list mode
and analyzed using the Becton Dickinson & Co. Consort 30 FACS data analysis software
package.
CofactorActivity Assays.
￿
The assay for cofactor activity for the factor I-mediated cleavage
of C3b and iC3b has been previously described (26). Briefly, 101 EAC1423b or EAC1423bi
prepared with 1251-C3 were incubated for 30 min at 37°C in a total volume of 100 ttl GVB
with factors to be tested for cofactor activity. Factors H and I in amounts indicated in the952
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text, 40 pl B95-8 or P3HR1-derived EBV or HCMV and 10' washed human erythrocytes
were added to 10' C3-bearing erythrocytes in various combinations. 80 pg of 3D9 mAb to
CRl was also included in certain samples, as indicated in the text. The cells were centrifuged
for 2 min at 12,000 g and the supernatants were removed and analyzed by SDS-PAGE under
reducing conditions followed by autoradiography. In some experiments, the cell pellets were
also extracted with SDS and analyzed by SDS-PAGE under reducing conditions. Quantities
of factors to be tested for cofactor activity for the factor I-mediated cleavage of C4b were
as follows for 10' cells: 20 ng factor I, 20 pg C4bp, and 40 pl EBV, in various combinations.
Decay-accelerating Activity Assays.
￿
Both classical and alternative pathway C3 convertase decay
rates were measured by mixing sheep E bearing the appropriate enzyme with the desired
concentration of either purified virus, control buffer, or known DAR For each time point
in the assay, 10' sheep E in 10 gl were combined with 40 pl of the factor under study, on
ice, and then warmed to 30°C quickly in a circulating water bath when timing began. When
marmoset or human erythrocytes were assessed for decay-accelerating activity, 108 primate
erythrocytes were included in the 40 pl. 80 pg ofmAb to CRl (3D9) was also included, where
specified. At timed intervals, samples of50 pl were removed and residual convertase activity
was measured by the addition of 1 ml guinea pig serum diluted 1 :50 in GVB containing
20 mM EDTA. After further incubation for 20 min at 37°C, the percent hemolysis was calcu-
lated and expressed as the reciprocal ofthe negative natural logarithm ofthe number of hemo-
lytic sites per cell: [-ln(1-y)].
C3 Binding Assays.
￿
Rosetting of lymphoid cells with sheep erythrocytes bearing comple-
ment intermediates was measured as follows. 5 x 105 TPA-treated virus-expressing B95-8
or P3HR1 cells, CRl-bearing TI human lymphocytes transformed with B95-8 virus and car-
ried as a lymphoblastoid cell line, or human peripheral blood monocytes (freshly isolated
by Ficoll-Hypaque gradient followed by elutriation) were incubated with 5 x 10'
complement-bearing sheep erythrocytes (EAC142, EAC1423b, EAC142iC3b, or EAC1423d)
in a total volume of 100 gl. After mixing, the cells were briefly pelleted (100 g, 3 min) and
the cell pellets were incubated without mixing for 1 h at 37°C. The cell pellets were gently
resuspended and rosetting was evaluated on a Zeiss phase contrast microscope. Cells with
four or more red cells attached to their surface were considered rosette-positive.
The dot blot immunoassay has been previously described (18, 54). Briefly, 10 pg of native
C3, C3b, C3dg, or C4 were immobilized on nitrocellulose paper. After blocking and wash
steps, paper strips containing the blots were incubated at 23°C for 60 min with 50 pl ofpurified
B95-8-derived EBV or TRIS/dextran virus gradient buffer as a negative control diluted to
2 .5 ml in wash buffer. The reagents to detect binding were a biotinylated mAb to the mem-
brane gp350 antigen of EBV (designated BOS-1) (18) streptavidin-horseradish peroxidase
(HRP) (Amersham Corp., Arlington Heights, IL) and 2,2'-azinolois(3-ethylbenthiazoline
sulfonic acid) (ABTS) chromogenic substrate (250 pg/ml ABTS, 0.03% H202 in citrate
buffer, pH 4.5). The assay was also performed in the reverse direction, with 2.5 pl ofpurified
EBV or virus gradient buffer immobilized on nitrocellulose paper followed, after blocking
and washing by 10 pg of the complement fragments. The detection system for this assay used
rabbit antisera to the complement fragments, biotinylated goat anti-rabbit IgG (Vector Labora-
tories, Inc., Burlingame, CA) streptavidin-HRP and ABTS substrate.
The same type of assay was performed using a previously described ELISA (18, 54) with
slight modifications. Microtitration plates were coated with either 5 pl of purified B95-8-derived
EBV, HCMV, or control buffer diluted to 50 pl with bicarbonate coating buffer. This coating
step proceeded for 18 h at 37°C in an uncovered plate, to allow dessication onto the plate.
This step has been found to increase the sensitivity ofthe assay. After blocking and washing,
10 4g/well of complement fragments were incubated in the wells, in duplicate, at 23°C for
1 h. The antibodies used for detection were mAbs to C3b, C3c, and C3d mixed together.
The remainder of the assay was carried out as described earlier.
Direct binding assays to assess EBV attachment to complement-coated erythrocytes were
also performed. 5 x 10' EACs in 50 pl were incubated in duplicate with 50 pd of purified
EBV (B95-8) for 30 min at 37°C with occasional mixing. The cells were washed twice in
PBS containing 0.2% BSA (PBS(BSA) and the cell pellets were then resuspended in purified
mAb to EBV gp350 (BOS-1) at a concentration of 10 pg/ml. Incubation proceeded at 37°Cfor 30 min followed by two washes. The cell pellets were then incubated with 50 PI of bi-
otinylated goat anti-mouse IgG, diluted 1 :1,000 (Kirkegaard & Perry Laboratories, Inc.)
for 30 min at 37°C. After washing, the pellets were resuspended in 50 PI of 125I_streptavidin
(Amersham Corp.) diluted 1 :20 in PBStBSA. Incubation proceeded at 37°C for 30 min after
which the cells were washed thoroughly, transferred to clean tubes, and counted in a gamma
counter (model 5260; Packard Instrument Co., Downers Grove, IL).
Results
C3cIs GeneratedDuring theIncubation ofEBVwith Serum.
￿
In the course ofour studies
ofcomplement activation by EBV (21), we observed that cleavage products not only
characteristic of iC3b, as expected, but also of C3c (Fig. 1), appeared during the
incubation of purified B95-8 strain EBV with immune human serum containing
1251-C3 (Fig. 2, lane 1). While minor amounts of the 68-kD and 46-kD C3 frag-
ments characteristic of fluid phase cleavage of C3b into iC3b were found, the most
striking feature was the presence of a 25-kD C3 fragment. The size and marked
radiolabeling of this fragment are consistent with the NH2-terminal a chain frag-
ment of C3c. Also observed were traces of a 43-kD fragment that could represent
the other a' chain fragment or C3dg, which has a molecular weight ofapproximately
this size and is poorly radiolabeled by the procedure used. In the control (Fig. 2,
lane 2), only intact C3 and minor traces of iC3b (68- and 46-kD bands) were seen.
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FIGURE 2 .
￿
C3c is generated duringthe incubation ofEBV with serum .
EBV(B95-8) was incubated with normal immune human serum (lane
1) or with EDTA-chelated normal immune human serum (lane 2) sup-
plemented with 1251-C3 for 30 min at 37°C followed by SDS-PAGE
analysis and autoradiography under reducing conditions . C3 a (110-
kD)andp(75-kD) chains are indicated . The migration positions and
molecularmasses (kD) ofthe marker proteins are shownon the right ;
the molecular masses of the observed bands are indicated on the left .
Althoughhuman serum contains cofactors for the factor 1-mediated cleavage ofC3b
to iC3b (factor H and C4bp), it lacks cofactors for the factor 1-mediated cleavage
ofiC3b into C3c and C3dg. Thus the appearance of aC3 fragment characteristic
of C3c after incubation of EBV with serum suggested to us that EBV either pos-
sessed the ability to degrade C3b and iC3b, or acted as a cofactor for their break-
down . These aspects were investigated in the following experiments .
EBVIs a Cofactorfor the Factor I-mediated Cleavage of C3b .
￿
To determine whether
purified EBV either possessedthe ability to directly cleave C3b or acted as acofactor
for C3b degradation by factor I, EAC142 1251-C3b were incubated for 30 min at
37'C with buffer or with various combinations of factor I, factor H, purified EBV,
or human erythrocytes (as a source of CR1) . Aftercentrifugation, the supernatants
were analyzed by SDS-PAGE under reducing conditions followed by autoradiog-
raphy . As shown in Fig . 3, supernatants of cells incubated with B95-8-derived EBV
together with factor I revealed the presence of the 106-kD a' and 75-kD R chains
indicative of the presence ofC3b as well as a 68-kD fragment characteristic of the
fluid phase cleavage of the a' chain C3b to generateiC3b (lane 5) . Sincethe EAC1423
were well washed before incubation with buffer or the other reagents, the presence
ofC3b and iC3b in the supernatant is most likely explained by spontaneous elution
of nonspecifically boundC3b from the cells and its degradation in the fluid phase.
Others have also observed degradation products characteristic of iC3b in similar
mixtures of factor I, cofactors, and immune complex-bound C3b and interpreted
these findings as indicating release and degradation of noncovalently bound C3b
(26) . The 68-kDfragmentwas also observed in supernatants ofmixtures containing
factors I andH (lane 3) and factor I and human E as a source of CRl (lane 4),
both ofwhich served as positive controls . The factor1-humanE mixture also gener-
ated a 25-kD fragment, which is characteristic ofC3c . The 46-kD a' chain fragment
of iC3b is poorly labeled by the method used and thus not seen in the autoradio-MOLD ET AL .
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FIGURE 3 .
￿
EBV is a cofactor for the factor
1-mediated cleavage of C3b . SDS-PAGE
analysis (reducing conditions) of 1251-C3
released from EAC1423bby incubation for
30 min at 37°C withGVB(lane 1) ; factor
I alone (lane 2) ; factor Iand factorH(lane
3) ; factor I and human E (lane 4) ; factor
I andEBV (1395-8) (lane 5) ; factorHalone
(lane 6) ; human E alone (lane 7) ; EBV
(1395-8) alone (lane 8). 2 ~Ig of factors H
and I, 40 gl ofEBV or 107 human eryth-
rocytes were used .
graph. Supernatants of cells incubated with buffer (lane 1) or with EBV (lane 8),
factorH (lane 6) orhumanE (lane 7) alone showed no cleavage of the C3b a' chain ;
a trace of the 68-kD fragment was seen in the supernatant of cells incubated with
factor I alone (lane 2) . Qualitatively identical results were obtained in two addi-
tional experiments ofthis type with two otherB95-8EBV preparations (not shown),
as well as in four experimentswith P3HR1-derivedEBV (see last section of Results) .
In addition to analyzingthe supernatants for the presence ofC3 derivatives, cell-
bound C3 fragments were also examined in a number of these studies . Mixtures
containing EAC3b together with factor I and either human E or EBV showed the
presence ofa 68-kD band characteristic ofiC3b (not shown) . Since a 68-kD band
was notfound on cellsfrom mixtures containing EAC3b together with either buffer,
factor I, human E, or EBV alone, its presence documents the generation of iC3b
from noncovalentlyboundC3bon the cell surfaceby factor I acting with eitherhuman
E or EBV as acofactor. In addition,EAC3b from all of thereaction mixtures showed
the presence of variable amounts of multiple high molecular mass bands (>100 kD)
reflecting the covalent attachment of the C3 a' chain, or its fragments to multiple
erythrocyte membrane constituents . Smallamounts oflowermolecularweight bands
were also found . Identification of specific bands in these gels was not possible due
to the complexity of the patterns .
These above data cumulatively indicate that EBV does not directly degrade C3b
but rather acts as a cofactor for the factor I-mediated cleavage offluid phase or cell-
boundC3b into iC3b. Because of the inability to identify specific cleavage products
ofC3 on the celldue to covalent and noncovalent a' chain fragment binding tomem-
brane constituents, as well as the inefficient radiolabeling ofC3dg and oftheCOOH-
terminal fragment ofiC3b, we chose to analyze complement fragments in the super-
natants in subsequent studies .
EBV Is a Cofactorfor the Factor I-mediated Cleavage of iC3b .
￿
To determine whether
EBV also possessed the ability to either degrade iC3b, or alternatively, acted as a
cofactor for iC3b degradation, EAC142 121I-iC3b were incubated for 30 min at 37°C
with buffer or with various combinations ofB95-8-derivedEBV and factor I . HCMV
another human herpesvirus, was used as a control . After centrifugation the super-
natants were analyzed by SDS-PAGE followed by autoradiography . As shown in Fig.956
￿
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FIGURE 4 .
￿
EBV is a cofactor for the factor I-medi-
ated cleavage ofiC3b. SDS-PAGE analysis (reducing
conditions) of 1251-iC3 released from EAC142iC3b
by incubation withGVB (lane 1) ; factor I alone (lane
2); HCMV alone (lane 3);HCMV and factorI (lane
4) ; EBV (B95-8) alone (lane 5) ; EBV (B95-8) and
factor I (lane 6) . 2 wg of factor I or 40 ul ofEBV
or HCMV were used .
4, supernatants ofcells incubated with EBV together with factor Irevealed the pres-
ence ofa 25-kD fragment, consistent with the N112-terminal a' chain fragment of
C3c (lane 6) . The apparent molecular weight of the released C3 fragment, deter-
mined by SDS-PAGE analyses undernonreducingconditions, was 139kD (not shown).
This is consistent with the valueof 146kD obtained by adding the molecular weights
of the NH2- and COON-terminal a' chain fragments of C3c (25 kD and 46 kD,
respectively) together with that of the R chain (75 kD). Much smaller amounts of
this fragment were released by factor I alone(lane2) and none was released sponta-
neously (lane 1) or by EBV alone(lane5) . HCMV did not show such activity (lanes
3 and 4) . Similar results were obtained in four additional studies of this type with
threedifferent preparations of1395-8-derived EBV These studies indicate thatEBV
is also a cofactor for the factor I-mediated cleavage of iC3b .
EBVIs a Cofactorfor the Factor I-mediated Cleavage ofC4b and iC4b .
￿
Similar studies
to those described above were carried out with EACI 1251-C4b in order to ascertain
whetherEBVwas alsoacofactor forthefactor I-mediated cleavage ofC4b. Asshown
in Fig . 5, supernatants of cells incubated with EBV (B95-8) together with factor
FIGURE 5 .
￿
EBV is a cofactor for the factor I-mediated cleavage
of C4b . SDS-PAGE analysis (reducing conditions) of 1251-C4 re-
leased from EAC14 by incubation with factor I alone (lane 1) ; factor
I andC4-bindingprotein (lane 2) ; factor IandEBV(B95-8) (lane
3) ; C4bp alone (lane 4) ; EBV (B95-8) alone (lane 5) . 20 ng offactor
I, 20 ug of C4bp or 40 gl ofEBV were used .2.0
I revealed thepresence of only a trace ofthe 89-kD a' chain together with the 77-kD
and 35-kD R and a chains, respectively (lane 3). In addition, two fragments with
molecular masses of 27 kD and 19 kD (lane 3), consistent with the presence of C4c,
were observed. The same fragments were observed in mixtures containing C4bp
and factor I (lane 2). These fragments were not released by factor I alone (lane 1),
C4bp alone (lane 4), or EBV alone (lane 5). Similar results were obtained in two
other studies of this type. These studies indicate that EBV is also a cofactor for the
factor I-mediated cleavage of both C4b and iC4b.
EBVAccelerates theDecay oftheAlternative, but notthe ClassicalPathway C3 Convertase.
￿
A
common property of several of the factor I cofactors is their ability to accelerate
decaydissociation of thealternative and/or classicalpathway C3 convertases. As shown
in Fig. 6, B95-8-derived EBV reduced the half-life of the nickel-stabilized alterna-
tive pathway C3 convertase, C3bBb, on sheep E from 21.5 to 7.8 min. Similar ac-
celerated decay was observed in the presence of factor H. Accelerated decay of the
nickel- or properdin-stabilized alternative pathway C3 convertases in the presence
of EBV was found in seven additional studies with four different preparations of
0.8
0.8
0.4
0.2
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FIGURE 6.
￿
EBVaccelerates the decayofthe
nickel-stabilized alternative pathwayC3 con-
vertase. SheepEbearingthenickel stabilized
alternative pathwayC3 convertase, C3b, Bb,
were incubated at 30°C with buffer, EBV
(1395-8), or factor H. Periodic samples were
incubated with EDTA guinea pig serum as a
source ofC3-C9, afterwhichlysis wasassessed
and expressed as -ln(1 - y).
FIGURE 7.
￿
EBVdoes notacceler-
ate the decay of the classical path-
way C3 convertase. EAC142 pre-
paredwith humancomponents and
nonoxidized C2 were incubated
with buffer, EBV(1395-8),or C4bp
at 30°C. Periodic sampleswere in-
cubated with EDTA guinea pig
serum as a source of C3-C9, after
which lysis was assessed and ex-
pressed as -ln(1 - y).958
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1395-8-derived EBV. Qualitatively identical results were obtained in two studies of
this type carried out with P3HR1-derived EBV.
In contrast, the same amount of EBV (1395-8) did not influence the decay rate
of the classical pathway C3 convertase, C4b2a, on sheep E as depicted in Fig. 7.
Similar results were obtained in two other studies of this type. However, C4bp re-
duced the half-life of the classical pathway C3 convertase from 20 to 10 min (Fig.
7). Thus, EBV accelerated the rate ofdecay of the alternative, butnotclassical pathway
C3 convertase.
EBVDoes Not Readily Bind to Cab.
￿
The above approaches indicated that EBV in-
teracted with factor Ito facilitate Cabcleavage and also produced alternative pathway
decayacceleration, likely also via an effect on C3b. Some, although not all such cofactors
and decay accelerators, bind C3b (see Fig. 12). Several approaches were used to assess
the potential C3b binding ability of EBV First, the possible ability of EAC3b to
form rosettes with TPA-treated B95-8 and P3HR1 cells was examined in several ex-
periments. No rosetting of the virus-expressing cells (in 300 lymphoid cells) with
EAC3b was obtained although all of the CRl-bearing T1 human lymphoblastoid
cells and most ofthe monocytestested in the same experiments formed large rosettes
(greater than six erythrocytes per leukocyte) with EAC3b. In a second approach,
EBV (1395-8) was incubated with C3b (and other C3 fragments) that had been im-
mobilized on nitrocellulose. Subsequent incubation with a biotinylated mAb to EBV
followed by streptavidin HRPand substratefailed to provideevidence forEBV binding.
This test system readilydetected EBV directly bound to the nitrocellulose. The same
assay performed with C3 fragments bound to the wells of microtitration plates also
failed to provide evidence for binding of EBV to C3b. This test carried out at one-
third normal ionic strength also did not provide evidence for EBV binding. These
assays were also performed in the reversedirection, i.e., by incubating C3b and other
C3 fragments with B95-8-derived EBV immobilized on either nitrocellulose or plastic
microtitration plate. Rabbit antibody to C3 followed by biotinylated goat anti-rabbit
Ig, streptavidin HRP, and substrate were added sequentially. These experiments
also failed to provide evidence for EBV bindingto C3b. Finally, purified EBV (1395-
8) was incubatedwith EAC3b. Possible binding of EBV was assessed by incubation
with an mAb to EBV followed by biotinylated goat anti-mouse Ig, and t25I-strepta-
vidin. The cells after washingwere examined for bound radioactivity. These studies
did not provide evidence for EBV binding to cell bound C3b. We conclude that
TABLE I
Marmoset Erythrocytes Do Not Accelerate C3bBb Decay
EAC3bBb were incubated at 30°C with human or marmoset erythrocytes in
the presence or absence of 3139 anti-CR1 mAb.
Erythrocytes T
min
Control` 22.5
Marmoset E 21 .5
Marmoset E + 3139 22.5
Human E 14
Human E + 3D9 20.5d .c
E
Z
m v
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FIGURE 8.
￿
B95-8 cells do not
bear CRI. FAGS analysis of the
reactivity of B95-8 cells with
various monoclonal antisera di-
rected againsthuman B cell an-
tigens. (A) Control. Reactivity
with anti-HLA-DQ (B), anti-
CRl (3D9) (C), HLA class I
(D), HLA-DR (E) and anti-BI
(F) are shown.
the interaction of EBV with C3b, although functionally significant, is too weak or
transitory to be directly demonstrated.
C3/C4 Cofactor and Decay-accelerating Activities Are Not Due to Crl Associated with or
Bound to EBV . Several approaches were used to determine whether the observed
C3 regulatory activities were due to CRI acquired from the B95-8 or P3HR1 cell
lines during cellular disruption or EBV maturation. As described in the previous
section, TPA-treated B95-8 cells failed to form rosettes with EAC3b. This very sen-
sitive assay is the standard functional test for CR1.
Since many of the assays were carried out with EBV derived from the B95-8 cell
line, which is of marmoset origin, we sought to determine whether marmoset CRl,
if it should be present in EBV derived from the cell line, would crossreact function-
ally with human complement components. We assessed marmoset erythrocytes, as
a source of marmoset CRl, for ability to accelerate decay of the C3bBb convertase
since this is notonly a sensitive test system for CR1, but also, marmoset cell-derived
EBV possesses this activity. However, as shown in Table I, marmoset erythrocytes
did not accelerate C3bBb decay while the positive control, human E, did so. The
latter activity was also inhibited by the 3D9 mAb to CRl, as anticipated . Qualita-
tively similarresults were obtained in twoother assays of this type with erythrocytes
from two marmosets. Thus marmoset CRI is not reactive with human C3bBb.
We also examined marmoset B95-8 cells, as well as human P3HR1 cells, for the
presence of immunochemically reactive CRl by FACS. As shown in Fig. 8 C, the
3D9 mAb to CRI failed to react with marmoset B95-8 cells. Several other mono-
clonal antisera directed against human B cell antigens were also examined. As shown,960
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FIGURE 9.
￿
Anti-CR1 does not block the
alternative pathway C3 convertase decay
accelerating activity of EBV. Sheep E
bearing the nickel-stabilized alternative
pathwayC3 convertase, C3bBb, were in-
cubated at 30°C with buffer, B95-8 EBV
B95-8 EBV + anti-CRI, human E as a
source ofCRI and humanE + anti-CR1.
Sampleswere processedas described in the
legend to Fig. 6.
good reactivity of the marmoset cells with antibody to a human common HLA class
I determinant (panel D), to human HLA-DR (panel E), and to the BI antigen (panel
F) was observed. HLA-DQwas not detected (panel B). Two anti-CRI mAbs (833M
and 44D) and a polyclonal antibody to CR1 also failed to detect CR1 on the B95-8
cells (not shown).
To examine the possibility that undetectable traces of immunochemically reactive
CRI possibly present on the cells might be incorporated into EBV, we assessed the
ability of monoclonal anti-CRI to inhibit the alternative pathway C3 convertase-
accelerating activity of B95-8 EBV. As shown in Fig. 9, the decay-accelerating ac-
tivity of B95-8-derived EBV was not altered by 3D9 anti-CRI whereas the same
amount o£ anti-CR1 reversed the decay-accelerating activity of CRI on human E.
Because of uncertainties about detection of marmoset CR1, studies were carried
out to assess the possible presence of human CRl on human EBVproducing cells
or EBV derived from the cells. As noted in the previous section, the P3HR1 EBV
producing cells also failed to rosette with EAC3b, the standard functional assay for
CRI. Human P3HR1 cells were also examined for the presence of CR1 by FAGS.
As shown in Fig. 10, P3HR1 cells failed to react with either 833M or 44D mAbs
to CRI (panel E), whereas T1 lymphoblastoid cells reacted with both antibodies
(panel F). B95-8 cells, as noted above, did not react with these antibodies (panel
D). An identical pattern of reactivity or nonreactivity was observed with 3D9 mAb
to CRI (not shown) . Thus human P3HR1 cells also do not bear immunochemically
detectable CRI .
Although CRl could not be detected on the virus-producing cells, we examined
whether undetectable traces of CR1 might account for the results by examining the
possible ability of anti-CR1 to block cofactor activity of EBV derived from the human
cell line. The 3D9 monoclonal anti-CRI examined is known to block CRI func-m
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FIGURE 10 . P3HR1 cells do
not bearCRl . FACS analysis of
the reactivity ofB95-8, P3HR1,
and TI lymphoblastoid cells
with anti-CRI mAbs. (A, B, and
C) The B95-8, P3HR1, and TI
controls. Reactivity of 833M
(solid line) and 440 (dolled line)
10'
￿
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10 .
￿
anti-CRI mAbs with B95-8 (D),
P3HR1(E) andTI (F) lympho-
blastoid cells are shown,
tional activities . In these studies EAC142 1251-C3b were incubated with various com-
binations of factor H, factor I, human E, P3HR1-derived EBV, and monoclonal
3139 anti-CRI . The supernatants were analyzed by SDS-PAGE as described earlier.
As shown in Fig. 11, supernatants of cells incubated with P3HR1-derived EBV to-
gether with factor I showed the presence of the 68-kD fragment characteristic of
iC3b (lane 6), as also observed with B95-8EBV (Fig . 3) . The 68-kD fragment was
also observed in mixtures containing factors I andH (lane 3) andfactor I andhuman
E (lane 8), but not in the control lanes (lanes 1, 2, 4, and 5) . Further cleavage was
FIGURE 11 .
￿
Anti-CRI does not block the fac-
tor I cofactor activity ofEBV for the cleavage
of C3b . SDS-PAGE analysis (reducing con-
ditions) of 1251-C3 released from EAC142
1251-C3b by incubation for 30 min at 37°C
with factorH alone (lane 1) ; factor I alone
(lane 2) ; factor H and factor I (lane 3) ;
P3HRI derived EBV alone (lane 4); human
E alone (lane 5); factor I and P3HR1-derived
EBV (lane 6) ; factor I, P3HRl-derivedEBV,
and 3139 monoclonal anti-CRI (lane 7) ; fac-
tor I andhumanE(lane 8); and factor I, hu-
man E, and 3139 monoclonal anti-CRI (lane
9) . 30 ng of factor 1, 500 ng of factor H, 40
pl of EBV, 10 1 human E, and 80 1xg of 3139
antibody were used; anti-CRI was prein-
cubated with EBV or human E for 30 min
at 37°C before addition to EAC142 1251-C3b.962
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FIGURE 12. Activity profiles of C3
and C4 regulatory proteins.
also observed in the samples containing erythrocytes. Ofconsiderable interest, mono-
clonal anti-CR1 did not block generation of the 68-kD fragment in reaction mix-
tures containing EAC3b, factor I, and P3HR1-derived EBV (lane 7) although it
efficiently blocked generation ofiC3b from Cabby factor I acting together with human
E (lane 9) . Similarresultswere obtained in another study with P3HR1-derived EBV.
The various studiesdescribed above rule out CR1 as responsible for thebiological
activities observed. Furthermore, the finding that marmoset B95-8 EBV as well as
P3HR1 EBV derived from marmoset andhumancells, respectively, possess the same
complement regulatory functions strongly suggests that EBV is responsible for the
functional properties.
Discussion
Anumber ofmolecules have been identified that regulate C3b and C4b activation
and processing either by acting as cofactors for factor I-dependent cleavage or by
accelerating the decay of the C3 convertases (Fig. 12). We have found complement
regulatory activities in purified preparations of EBV derived from virus-producing
marmoset and human B lymphoblastoid cells. In the presence of factor 1, EBV en-
hanced the cleavage of bound C3b to iC3b, iC3b to C3c and C3dg, C4b to iC4b,
and iC4b to C4c and C4d. No breakdown of C3b, iC3b, or C4b by EBV was seen
in theabsenceof factor I, indicating that the EBV preparations did not contain pro-
teases capable of degrading these proteins. EBV also accelerated the decay of the
alternative pathway, but not the classical pathway C3 convertase. This pattern of
reactivity differs from that of all other reported serum, cell membrane, and viral
cofactors (Fig. 12). For example, the serum proteins factor H and C4bp both act
as cofactors forthe cleavage of C3b to iC3b under physiological conditions (27, 28,
35) and as DAFs for the alternative pathway and classical pathway C3 convertases
respectively (39, 40). The membrane glycoprotein CRl is a cofactor forthe cleavage
of bound C3b and iC3b as well as C4b and iC4b (26, 27, 36), it also is a decay
accelerating factor for both convertases (41, 42). The membrane protein DAF has
no cofactor activity but decay accelerating activity for both convertases (43, 44).
Anothercell surface regulatory factor, MCP, enhances the cleavage of C3b to iC3b
by factor I but lacks decay-accelerating activity for both convertases (38). Neither
the activity of MCP in the cell membrane, nor its action on cell-bound C3b has
as yet been examined.
C3b Binding - + + + - t + +
Cofactor for Cleavage of Cab by 1 + - + - - + + +
Cofactor for Cleavage of iC3b by I + + + - - - -
Alternative Pathwa
C3 Convertase Decay + + + - + - + -
Cob Binding - - + - + - +
Cofactor for Cleavage of C4b by I + + - + - +
Cofactor for Cleavage of iC4b by I + + - - - +
Classical Pathway
C3 Convertase Decay - - + - + - - +MOLD ET AL.
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The spectrum of activities ofEBV is most similar to that of CR1, but differs in
that EBVexpressing cells, incontrast to CRl-bearing cells, do not rosette with C3b-
coated erythrocytes. This is the primary functional assay for CRI. A second distin-
guishing feature is its inability to accelerate the decay of the classical pathway C3
convertase. Nevertheless, multiple otherstudies were carriedout to determine whether
the observed activities might represent the actions of CRl acquired from the virus
producing cell lines. Among these, we examined whether marmoset erythrocytes,
as asource ofmarmoset CR1, would accelerate the decay ofthe alternative pathway
C3 convertase as do human CRI and EBV Marmoset erythrocytes undoubtedly
bear CR1 as do other primate erythrocytes (55), and have been reported to exhibit
C3b(CRI)-dependentrosetting inasomewhat unconventional test system (56). How-
ever, erythrocytes from two marmosets lacked the ability to accelerate decay of the
alternative pathway C3 convertase, although human E possessed such activity and
this activity was inhibited by anti-CR1. Next we assessed whether an mAb to CRl
could reverse the decay-accelerating activity of B95-8 EBV No effect on the decay
rate was noted, although the same antibody reversed the decay-accelerating activity
ofCR1 on human erythrocytes. We also evaluated whether CRI could be detected
on TPA-treated marmoset B95-8 cells with three mAbs to CR1 as well as a poly-
clonal antibody to CRl. No reactivity was observed. Since the B95-8 cell line is of
marmoset origin and the antibodies are directed againsthuman proteins, we exam-
ined multiple antisera to human cell surface antigens to determine whether cross-
reactivity ofthe antisera with marmoset cell surfaceantigens iscommonly observed.
Goodreactivity with antibody to a common HLAclassIdeterminant, toHLA-DR,
and to the human B1 antigen was observed. Although HLA-DQwas not detected
on the marmoset cells, this finding must be interpreted with caution since human
B cells and lymphoblastoid cells vary considerably in their expression of the two
MHC class II determinants, HLA-DQ and HLA-DR.
The strong crossreactivity ofantibodies to human MHC class I, HLA-DR, and
B1 antigens with the equivalent antigens on the marmoset B95-8 cells coupled with
the absence ofreactivity withmonoclonal and polyclonal antibodies to human CRI
suggested that the virus-producing marmoset B95-8 cells lack CRI. The failure of
anti-CRI to block the decay-accelerating activity of B95-8-derived EBV also im-
plied thatCRl wasnot responsible forthe observed activity. Finally, the studies with
marmoset erythrocytes suggestedthat marmoset CRI, even ifpresent, wouldbe un-
able to accelerate human C3bBb decayasdid EBV. Nevertheless, some uncertainty
remained becauseofthe different species involved. To definitively eliminatethe pos-
sibility that CR1 in the EBV preparations was responsible for the observed activi-
ties, we carried out a number ofstudies with human P3HR1 EBVproducing cells
and with EBV purified from the human cells.
First, weevaluated whetherP3HR1 cellswould rosette withC3b-bearing erythro-
cytes. No reactivity was observed although known CRI-bearing controls readily
rosetted. Second, we assessed the presence of CR1 on the P3HR1 cells with three
mAbs to CRI. No reactivity was found although the antibodies reacted with CRI
bearing, non-EBVproducing human B lymphoblastoid cells. Third, the factor I
cofactor activity ofpurified EBV from the P3HR1-bearing cells was not blocked by
the 3D9 mAb to CR1 although this antibody inhibited human E-mediated, CR1-
dependent cofactor activity in the same experiments.964
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The above studies cumulatively indicate that CRl is not responsible for the factor
I cofactor anddecay-accelerating activities exhibited by purified EBV preparations.
We have not directly examined whetherthe observed activities areproperties ofEBV
or of a cellular protein other than CRl incorporated into, or attached to EBV. We
feel, however, that the regulatory properties are most likely virus related for three
reasons. First, the spectrum of activities differs from that of any of the known cel-
lular or serum cofactors (Fig. 12). Second, EBV derives its envelope from the nu-
clear membrane, not the plasma membrane; furthermore, cellular proteins tend to
be excluded from viral envelopes. Also, thevirus-containing supernatantis subjected
to ultrafiltration before initiating purification, and isolation is by banding in a rate
zonal density gradient. Finally, and most telling, EBV preparations derived from
both marmoset andhuman cell lines possessed thesame decay-accelerating and factor
I cofactor activities. It is unlikely that cells from the two species possess a principle
that regulates human complement components and that is incorporated into EBV
from the two cell lines. It is more probable that the functional regulatory activities
are properties of a protein encoded by the viral genome. A final answer, however,
must await the isolation and characterization of the factor.
Approximately 2 x 109 EBV particles possessed somewhat less factor I cofactor
activity forC3b cleavage than 10' human erythrocytes (Fig. 3). The human erythro-
cytes likely possess -1,000 CRl per cell (57) since they were preselected for high
activity. The regulatory activity of EBV is clearly less than that of CRl in this test
system, although it is within the published range of activity of other regulatory pro-
teins. For example, MCP is more than 50 times as active as factor H in acting as
a factor I cofactor for C3b cleavage (38). Factor H is 2 times more active than CR1
which in turn is 17 timesmore efficient than C4bp (58). Theefficiency ofthese factors
in this test system thus spans more than a 3-log range. Clearly, such quantitative
assessments in nonphysiological, nonoptimized test systems do not reflect biological
effectiveness in vivo. This is particularly true ofEBV, which is unlikely to have evolved
and maintained this trait if it did not provide a protective advantage for the virus.
For the cofactor and decay-accelerating activities of EBV to be biologically
meaningful, they would have to act on C3b boundto the same viral particle because
multiple EBV particleswould not likely be foundin close proximity in vivo. Although
both CRl (59) and DAF (44), two ofthe membrane-associated complement regula-
tory proteins, possess the abiltiy to act on C3b attached to the same cell (intrinsic
activity), the relative intrinsic versus extrinsic activity (for C3b bound to othercells
or immune complexes) remains to be determined for MCP and HSV gC as well
as for EBV.
Otherherpes viruses have also been found to encode variousproteins that interact
with the humoral immune system. Thus, infection ofhuman cellswith otherherpes
viruses, includingHSV1, HSV2, cytomegalovirus, andvaricella zoster virus results
in the appearance on the cell surface of virally encoded receptors for the Fc portion
of human IgG (60-62). HSV1 also induces the appearance of a C3b receptor in
the plasma membrane of infected cells (46, 63), and this has been identified as a
viral glycoprotein, gC (45, 47). This viral C3b receptor is reactive with an mAb
to human CRl (46); it also modulates complement activation as it has decay-
accelerating activity for the alternative pathway C3 convertase, and interferes with
the interaction of C3b with C5, although it lacks cofactor activity (45). RecentlyMOLD ET AL.
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gC ofHSV2 has been reported to possess the ability to bind iC3 (48). Otherhuman
pathogens including bacteria (64, 65) and fungi (66, 67) have been found to possess
Fc or C3 binding properties. Although the biological significance of these various
activities is far from clear, it is probable that they have evolved to provide survival
value for the pathogens.
In this regard, the various EBV complement regulatory activities reported in this
paper may enable EBV and EBVinfectedcells to evade destruction by humoralim-
mune mechanisms. SinceEBV and EBVinfectedcells activate complement, thevirions
as well as the infected cells would become coated with Cab as well as other comple-
ment components on contact with plasma. This couldfacilitate cytolytic destruction
of the virus or virus-infected cell by either complement- or lymphocyte-dependent
cytolytic mechanisms (68); it could also augment opsonization and phagocytic de-
struction by complement receptor-bearing cells (23). Furthermore, the ability of
the virus to accelerate the decay of the alternative pathway C3 convertase would re-
tard additional activation, while the cofactor activity for both factor I-mediated
cleavages of C3 as well as C4 would rapidly convert bound C3b and C4b to bound
C3dg andC4d whichdo notreadily interact with phagocytic CRl andCR3 receptors.
The ability of EBV to facilitate the degradation of C3b on the viral surface to C3dg
mayrestore infectivity by permitting the virusto again bind to CR2 viaC3dg. These
various activities could thus allbe viewed as promotingviral survival. Sincethe effects
on EBV infectivity can be experimentally determined, further study will indicate
whetherthey do indeed permit EBV to evade destruction by complement- and cell-
dependent host defense mechanisms .
Summary
Serum incubatedwith purified EBV was found to contain C3 cleavage fragments
characteristic of C3c. Since thecofactors necessary forsuch cleavage ofC3b by factor
I are not normally present in serum, EBV was tested for factor I cofactor activity.
Purified EBV from both human and marmoset EBVproducing cell lines was found
to act as a cofactor for the factor I-mediated breakdown C3b to iC3b and iC3b to
C3c and C3dg. EBV also acted as a cofactor for the factor I-mediated cleavage of
C4b to iC4b and iC4b to C4c and C4d. EBV from both the human and marmoset
cell lines accelerated the decay of the alternative pathway C3 convertase. The clas-
sical pathway C3 convertase was unaffected. Multiple lines of evidence eliminated
the possibility that marmoset or human CRl was responsible forthe functional ac-
tivities of EBV preparations. The spectrum of activities was different from CR1 in
that EBVand EBVexpressingcell linesfailed to rosette with C3bor particlesbearing
C3b, the primary functional assay for CR1, and EBV did not accelerate classical
pathway C3 convertase decay, another property ofCR1. In addition, CRl couldnot
be detected immunologically on marmoset or human EBVexpressingcellsand mAbs
to CR1 failed to alter EBVproduced decay acceleration and factor I cofactor activi-
ties, although the antibodies blocked the same CR1-dependent functional activities.
The multiple complement regulatory activities exhibited by purified EBV derived
from human and marmoset cells differ from those of any of the known C3 or C4
regulatory proteins. These various activities would be anticipated to provide sur-
vivalvalue forthe virus by subverting complement- andcell-dependent host defense
mechanisms.966
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